🎉 M&A multiples are live!
Check it out!

Integral Diagnostics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Integral Diagnostics and similar public comparables like Burjeel Holdings, PureHealth, and Ramsay Health.

Integral Diagnostics Overview

About Integral Diagnostics

Integral Diagnostics is Australia’s fourth-largest diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.


Founded

2008

HQ

Australia
Employees

2.0K+

Financials

LTM Revenue $374M

LTM EBITDA $71.4M

EV

$834M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Integral Diagnostics Financials

Integral Diagnostics has a last 12-month revenue of $374M and a last 12-month EBITDA of $71.4M.

In the most recent fiscal year, Integral Diagnostics achieved revenue of $297M and an EBITDA of $4.3M.

Integral Diagnostics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Integral Diagnostics valuation multiples based on analyst estimates

Integral Diagnostics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $278M $297M XXX XXX XXX
Gross Profit $215M $265M XXX XXX XXX
Gross Margin 77% 89% XXX XXX XXX
EBITDA $58.5M $4.3M XXX XXX XXX
EBITDA Margin 21% 1% XXX XXX XXX
Net Profit $9.2M $15.8M XXX XXX XXX
Net Margin 3% 5% XXX XXX XXX
Net Debt $63.2M $120M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Integral Diagnostics Stock Performance

As of March 14, 2025, Integral Diagnostics's stock price is AUD 2 (or $1).

Integral Diagnostics has current market cap of AUD 818M (or $517M), and EV of AUD 1.3B (or $834M).

See Integral Diagnostics trading valuation data

Integral Diagnostics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$834M $517M XXX XXX XXX XXX $0.06

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Integral Diagnostics Valuation Multiples

As of March 14, 2025, Integral Diagnostics has market cap of $517M and EV of $834M.

Integral Diagnostics's trades at 2.2x LTM EV/Revenue multiple, and 11.7x LTM EBITDA.

Analysts estimate Integral Diagnostics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Integral Diagnostics and 10K+ public comps

Integral Diagnostics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $834M XXX XXX XXX
EV/Revenue 2.4x XXX XXX XXX
EV/EBITDA 20.5x XXX XXX XXX
P/E -51.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 41.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Integral Diagnostics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Integral Diagnostics Valuation Multiples

Integral Diagnostics's NTM/LTM revenue growth is 28%

Integral Diagnostics's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Over next 12 months, Integral Diagnostics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Integral Diagnostics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Integral Diagnostics and other 10K+ public comps

Integral Diagnostics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 7% XXX XXX XXX XXX
EBITDA Margin 12% XXX XXX XXX XXX
EBITDA Growth -93% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 40% XXX XXX XXX XXX
Revenue per Employee $0.2M XXX XXX XXX XXX
Opex per Employee $0.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 65% XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue 86% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Integral Diagnostics Public Comps

See public comps and valuation multiples for Hospitals & Clinics and Medical Imaging & Diagnostics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Burjeel Holdings XXX XXX XXX XXX XXX XXX
PureHealth XXX XXX XXX XXX XXX XXX
Ramsay Health XXX XXX XXX XXX XXX XXX
Compass Pathways XXX XXX XXX XXX XXX XXX
Bangkok Dusit Medical Services XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Integral Diagnostics M&A and Investment Activity

Integral Diagnostics acquired  XXX companies to date.

Last acquisition by Integral Diagnostics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Integral Diagnostics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Integral Diagnostics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Integral Diagnostics

When was Integral Diagnostics founded? Integral Diagnostics was founded in 2008.
Where is Integral Diagnostics headquartered? Integral Diagnostics is headquartered in Australia.
How many employees does Integral Diagnostics have? As of today, Integral Diagnostics has 2.0K+ employees.
Who is the CEO of Integral Diagnostics? Integral Diagnostics's CEO is Dr. Ian Kadish.
Is Integral Diagnostics publicy listed? Yes, Integral Diagnostics is a public company listed on ASX.
What is the stock symbol of Integral Diagnostics? Integral Diagnostics trades under IDX ticker.
When did Integral Diagnostics go public? Integral Diagnostics went public in 2015.
Who are competitors of Integral Diagnostics? Similar companies to Integral Diagnostics include e.g. Burjeel Holdings, PureHealth, Ramsay Health, Compass Pathways.
What is the current market cap of Integral Diagnostics? Integral Diagnostics's current market cap is $517M
What is the current revenue of Integral Diagnostics? Integral Diagnostics's last 12-month revenue is $374M.
What is the current EBITDA of Integral Diagnostics? Integral Diagnostics's last 12-month EBITDA is $71.4M.
What is the current EV/Revenue multiple of Integral Diagnostics? Current revenue multiple of Integral Diagnostics is 2.2x.
What is the current EV/EBITDA multiple of Integral Diagnostics? Current EBITDA multiple of Integral Diagnostics is 11.7x.
What is the current revenue growth of Integral Diagnostics? Integral Diagnostics revenue growth between 2023 and 2024 was 7%.
Is Integral Diagnostics profitable? Yes, Integral Diagnostics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.